...
首页> 外文期刊>Journal of the American College of Surgeons >Prognostic significance of ploidy, MIB-1 proliferation marker, and p53 in renal cell carcinoma.
【24h】

Prognostic significance of ploidy, MIB-1 proliferation marker, and p53 in renal cell carcinoma.

机译:倍性,MIB-1增殖标志物和p53在肾细胞癌中的预后意义。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Pathologic stage is currently the best prognostic factor for predicting outcomes in renal cell carcinoma. The objective of this study was to evaluate the role of DNA ploidy, p53, and Ki-67 (MIB-1) as individual and combined prognostic factors for survival in patients with renal cell carcinoma (RCC). STUDY DESIGN: From 1995 to 2004, 117 patients (78 men and 39 women; mean age 57.34 years), undergoing partial (n = 22) or radical (n = 95) nephrectomy for renal cell carcinoma were retrospectively analyzed. Analysis of MIB-1, p53, and DNA ploidy was performed. Disease-free and overall survival was calculated using Cox proportional hazard models. A combined score was given to incorporate p53, MIB-1, and ploidy as a single variable. RESULTS: On univariate analysis, tumor size, nuclear grade, MIB-1 <10% (p = 0.0059), ploidy (p = 0.0124), pathologic stage group, metastasis at time of operation, and combined score (p = 0.0024) were markedly associated with disease-free survival. On multivariate analysis, only metastasis and pathologic stage were pronounced. For overall survival, size, nuclear grade, MIB-1 <10% (p = 0.0167), pathologic stage group, metastasis, and combined score (p = 0.0456) were pronounced on univariate analysis. Only metastasis was pronounced on multivariate analysis. CONCLUSIONS: We incorporated a combined score to evaluate MIB-1, ploidy, and p53 as a single variable. A combined score is able to give a stronger predictive value of the cellular characteristics of each tumor. Individually and combined with p53, MIB-1, and ploidy were of prognostic significance on univariate analysis. Pathologic stage and presence of metastasis remain the best predictors of disease-free survival.
机译:背景:病理分期是目前预测肾细胞癌预后的最佳预后因素。这项研究的目的是评估DNA倍性,p53和Ki-67(MIB-1)作为个体和联合预后因素在肾细胞癌(RCC)患者生存中的作用。研究设计:从1995年至2004年,回顾性分析了117例接受部分肾切除术(n = 22)或根治性肾切除术(n = 95)的肾细胞癌患者(男性78例,女性39例,平均年龄57.34岁)。进行了MIB-1,p53和DNA倍性分析。使用Cox比例风险模型计算无病生存期和总生存期。综合得分将p53,MIB-1和倍性作为单个变量纳入。结果:单因素分析显示,肿瘤大小,核分级,MIB-1 <10%(p = 0.0059),倍性(p = 0.0124),病理分期,手术时转移和综合评分(p = 0.0024)为与无病生存期显着相关。在多变量分析中,仅转移和病理分期明显。对于总生存期,单因素分析显示有明显的大小,核分级,MIB-1 <10%(p = 0.0167),病理分期,转移和综合评分(p = 0.0456)。在多变量分析中仅转移明显。结论:我们纳入了综合评分,以评估MIB-1,倍性和p53作为单个变量。综合得分能够为每个肿瘤的细胞特征提供更强的预测价值。单变量分析与p53,MIB-1和倍性结合在一起具有预后意义。病理阶段和转移的存在仍然是无病生存的最佳预测指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号